• Climb Bio adopted a 2021 Equity Incentive Plan, effective immediately before its IPO date, replacing the 2019 plan for new grants.
• Share pool set at 5,216,105 shares, including 2,558,790 new shares, with up to 2,657,315 shares recycled from the prior plan.
• Automatic annual increases set at 5% of shares outstanding from Jan. 1, 2022 through Jan. 1, 2026, subject to board reduction.
• Non-employee director pay capped at USD 750,000 per year, rising to USD 1 million for a director first appointed or elected that year.
• Options or SARs carry a maximum 10-year term, with post-termination exercise windows of 3 months, 12 months for disability, 18 months for death.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-261716), on June 08, 2026, and is solely responsible for the information contained therein.